Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date
European Patent Office: These 69 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027
The content of this page is licensed under a Creative Commons Attribution 4.0 International License.
Generic Entry Dates in Other Countries
Friedman, Yali, "European Patent Office: These 69 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can BRILINTA (ticagrelor) generic drug versions launch in the European Patent Office?
Generic name: ticagrelor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 21, 2026
Generic Entry Controlled by: European Patent Office Patent 2,056,832
This drug has sixty-two patent family members in thirty-five countries. There has been litigation on patents covering BRILINTA
See drug price trends for BRILINTA.
The generic ingredient in BRILINTA is ticagrelor. There are twenty-one drug master file entries for this API. Twenty-nine suppliers are listed for this generic product. Additional details are available on the ticagrelor profile page.
When can LIVDELZI (seladelpar lysine) generic drug versions launch in the European Patent Office?
Generic name: seladelpar lysine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 13, 2026
Generic Entry Controlled by: European Patent Office Patent 1,937,065
LIVDELZI is a drug marketed by Gilead Sciences Inc. There are six patents protecting this drug.
This drug has one hundred and thirty-eight patent family members in forty-six countries.
The generic ingredient in LIVDELZI is seladelpar lysine. One supplier is listed for this generic product. Additional details are available on the seladelpar lysine profile page.
When can ESBRIET (pirfenidone) generic drug versions launch in the European Patent Office?
Generic name: pirfenidone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 22, 2026
Generic Entry Controlled by: European Patent Office Patent 1,940,364
ESBRIET is a drug marketed by Legacy. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has two hundred and sixty-six patent family members in forty-six countries. There has been litigation on patents covering ESBRIET
See drug price trends for ESBRIET.
The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.
When can ESBRIET (pirfenidone) generic drug versions launch in the European Patent Office?
Generic name: pirfenidone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 22, 2026
Generic Entry Controlled by: European Patent Office Patent 2,431,025
ESBRIET is a drug marketed by Legacy. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has two hundred and sixty-six patent family members in forty-six countries. There has been litigation on patents covering ESBRIET
See drug price trends for ESBRIET.
The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.
When can ZUNVEYL (benzgalantamine gluconate) generic drug versions launch in the European Patent Office?
Generic name: benzgalantamine gluconate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 22, 2026
Generic Entry Controlled by: European Patent Office Patent 1,940,817
Patent Title: AMPLIFICATEURS CHOLINERGIQUES DE PERMÉABILITÉ DE LA BARRIÈRE SANG-CERVEAU AMÉLIORÉE POUR LE TRAITEMENT DE MALADIES ACCOMPAGNÉES D'UNE DÉFICIENCE COGNITIVE (CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT)
ZUNVEYL is a drug marketed by Alpha Cognition. There are four patents protecting this drug.
This drug has twenty-seven patent family members in eighteen countries. There has been litigation on patents covering ZUNVEYL
The generic ingredient in ZUNVEYL is benzgalantamine gluconate. One supplier is listed for this generic product. Additional details are available on the benzgalantamine gluconate profile page.
When can CRESEMBA (isavuconazonium sulfate) generic drug versions launch in the European Patent Office?
Generic name: isavuconazonium sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 25, 2026
Generic Entry Controlled by: European Patent Office Patent 1,902,708
Patent Title: Compositions pharmaceutiques stabilisées et solides contenant au moins un médicament et procédé d'élaboration (Drug comprising stabilized pharmaceutical solid compositions and processes for their preparation)
This drug has thirty-two patent family members in nineteen countries. There has been litigation on patents covering CRESEMBA
See drug price trends for CRESEMBA.
The generic ingredient in CRESEMBA is isavuconazonium sulfate. One supplier is listed for this generic product. Additional details are available on the isavuconazonium sulfate profile page.
When can CRESEMBA (isavuconazonium sulfate) generic drug versions launch in the European Patent Office?
Generic name: isavuconazonium sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 25, 2026
Generic Entry Controlled by: European Patent Office Patent 2,068,842
Patent Title: FORMES GALÉNIQUES SOLIDES STABILISÉES CONTENANT UN PRINCIPE ACTIF ET DICITRATE DU TRIMAGNÉSIUM COMME DESSICCATEUR ET LEUR PROCÉDÉ DE PRODUCTION (ACTIVE INGREDIENT AND TRIMAGNESIUMDICITRATE AS DESICCANT CONTAINING STABILISED SOLID MEDICINAL FORMS AND METHOD FOR THE PRODUCTION THEREOF)
This drug has thirty-two patent family members in nineteen countries. There has been litigation on patents covering CRESEMBA
See drug price trends for CRESEMBA.
The generic ingredient in CRESEMBA is isavuconazonium sulfate. One supplier is listed for this generic product. Additional details are available on the isavuconazonium sulfate profile page.
When can TYMLOS (abaloparatide) generic drug versions launch in the European Patent Office?
Generic name: abaloparatide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2026
Generic Entry Controlled by: European Patent Office Patent 2,073,789
Patent Title: COMPOSITION STABLE D'UNE PROTÉINE ANABOLIQUE OSSEUSE QUI EST UN ANALOGUE DE PTHRP, ET SES EMPLOIS (A STABLE COMPOSITION COMPRISING A BONE ANABOLIC PROTEIN, NAMELY A PTHRP ANALOGUE, AND USES THEREOF)
This drug has fifty-six patent family members in twenty-nine countries. There has been litigation on patents covering TYMLOS
See drug price trends for TYMLOS.
The generic ingredient in TYMLOS is abaloparatide. One supplier is listed for this generic product. Additional details are available on the abaloparatide profile page.
When can TYMLOS (abaloparatide) generic drug versions launch in the European Patent Office?
Generic name: abaloparatide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2026
Generic Entry Controlled by: European Patent Office Patent 2,957,278
Patent Title: COMPOSITIONS STABLES CONTENANT PTHRP ET LEUR EMPLOI (A STABLE COMPOSITION COMPRISING PTHRP AND USES THEREOF)
This drug has fifty-six patent family members in twenty-nine countries. There has been litigation on patents covering TYMLOS
See drug price trends for TYMLOS.
The generic ingredient in TYMLOS is abaloparatide. One supplier is listed for this generic product. Additional details are available on the abaloparatide profile page.
When can COTELLIC (cobimetinib fumarate) generic drug versions launch in the European Patent Office?
Generic name: cobimetinib fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 05, 2026
Generic Entry Controlled by: European Patent Office Patent 1,934,174
COTELLIC is a drug marketed by Genentech Inc. There are seven patents protecting this drug.
This drug has two hundred and seven patent family members in forty-six countries.
See drug price trends for COTELLIC.
The generic ingredient in COTELLIC is cobimetinib fumarate. One supplier is listed for this generic product. Additional details are available on the cobimetinib fumarate profile page.
When can INREBIC (fedratinib hydrochloride) generic drug versions launch in the European Patent Office?
Generic name: fedratinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 26, 2026
Generic Entry Controlled by: European Patent Office Patent 1,951,684
INREBIC is a drug marketed by Bristol-myers. There are five patents protecting this drug.
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering INREBIC
See drug price trends for INREBIC.
The generic ingredient in INREBIC is fedratinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the fedratinib hydrochloride profile page.
When can BEVYXXA (betrixaban) generic drug versions launch in the European Patent Office?
Generic name: betrixaban
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2026
Generic Entry Controlled by: European Patent Office Patent 1,948,608
Patent Title: SELS PHARMACEUTIQUES ET POLYMORPHES DU N-(5-CHLORO-2-PYRIDINYL)-2-[[4-[(DIMETHYLAMINO)IMINOMETHYL]BENZOYL]AMINO]-5-METHOXY-BENZAMIDE, UN INHIBITEUR DU FACTEUR X (PHARMACEUTICAL SALTS AND POLYMORPHS OF N-(5-CHLORO-2-PYRIDINYL)-2-[[4-[(DIMETHYLAMINO)IMINOMETHYL]BENZOYL]AMINO]-5-METHOXY-BENZAMIDE , A FACTOR XA INHIBITOR)
BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug.
This drug has sixty-seven patent family members in twenty-six countries. There has been litigation on patents covering BEVYXXA
See drug price trends for BEVYXXA.
The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.
When can PYLARIFY (piflufolastat f-18) generic drug versions launch in the European Patent Office?
Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: European Patent Office Patent 3,699,162
PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.
This drug has one hundred and eighteen patent family members in twenty-seven countries.
See drug price trends for PYLARIFY.
The generic ingredient in PYLARIFY is piflufolastat f-18. Two suppliers are listed for this generic product. Additional details are available on the piflufolastat f-18 profile page.
When can PYLARIFY TRUVU (piflufolastat f-18) generic drug versions launch in the European Patent Office?
Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: European Patent Office Patent 3,699,162
PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.
This drug has one hundred and eighteen patent family members in twenty-seven countries.
The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. Two suppliers are listed for this generic product. Additional details are available on the piflufolastat f-18 profile page.
When can KORSUVA (difelikefalin acetate) generic drug versions launch in the European Patent Office?
Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: European Patent Office Patent 2,064,228
KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug.
This drug has fifty-three patent family members in twenty-seven countries. There has been litigation on patents covering KORSUVA
See drug price trends for KORSUVA.
The generic ingredient in KORSUVA is difelikefalin acetate. One supplier is listed for this generic product. Additional details are available on the difelikefalin acetate profile page.
When can SOFDRA (sofpironium bromide) generic drug versions launch in the European Patent Office?
Generic name: sofpironium bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 13, 2026
Generic Entry Controlled by: European Patent Office Patent 1,948,596
SOFDRA is a drug marketed by Botanix Sb. There are twenty patents protecting this drug.
This drug has one hundred and sixty-seven patent family members in twenty-six countries. There has been litigation on patents covering SOFDRA
The generic ingredient in SOFDRA is sofpironium bromide. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the sofpironium bromide profile page.
When can SOFDRA (sofpironium bromide) generic drug versions launch in the European Patent Office?
Generic name: sofpironium bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 13, 2026
Generic Entry Controlled by: European Patent Office Patent 1,957,451
SOFDRA is a drug marketed by Botanix Sb. There are twenty patents protecting this drug.
This drug has one hundred and sixty-seven patent family members in twenty-six countries. There has been litigation on patents covering SOFDRA
The generic ingredient in SOFDRA is sofpironium bromide. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the sofpironium bromide profile page.
When can AXUMIN (fluciclovine f-18) generic drug versions launch in the European Patent Office?
Generic name: fluciclovine f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: European Patent Office Patent 1,978,015
Patent Title: COMPOSE PRECURSEUR DE COMPOSE ORGANIQUE MARQUE A L'HALOGENE RADIOACTIF (PRECURSOR COMPOUND OF RADIOACTIVE HALOGEN LABELED ORGANIC COMPOUND)
AXUMIN is a drug marketed by Blue Earth. There are eight patents protecting this drug.
This drug has thirty patent family members in sixteen countries. There has been litigation on patents covering AXUMIN
The generic ingredient in AXUMIN is fluciclovine f-18. One supplier is listed for this generic product. Additional details are available on the fluciclovine f-18 profile page.
When can ZTALMY (ganaxolone) generic drug versions launch in the European Patent Office?
Generic name: ganaxolone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: European Patent Office Patent 1,959,966
Patent Title: FORMES GALÉNIQUES DE GANAXOLONE ET PROCÉDÉS DE PREPARATION ET D'UTILISATION DE CELLES-CI (GANAXOLONE FORMULATIONS AND METHODS FOR THE MAKING AND USE THEREOF)
ZTALMY is a drug marketed by Immedica Pharma. There are eleven patents protecting this drug.
This drug has fifty patent family members in sixteen countries. There has been litigation on patents covering ZTALMY
See drug price trends for ZTALMY.
The generic ingredient in ZTALMY is ganaxolone. One supplier is listed for this generic product. Additional details are available on the ganaxolone profile page.
When can ZUBSOLV (buprenorphine hydrochloride; naloxone hydrochloride) generic drug versions launch in the European Patent Office?
Generic name: buprenorphine hydrochloride; naloxone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: European Patent Office Patent 2,101,740
Patent Title: NOUVELLE COMPOSITION PHARMACEUTIQUE NON SUSCEPTIBLE D'ABUS COMPRENANT DES OPIOÏDES (NEW NON-ABUSABLE PHARMACEUTICAL COMPOSITION COMPRISING OPIOIDS)
This drug has sixty-two patent family members in thirty-two countries. There has been litigation on patents covering ZUBSOLV
See drug price trends for ZUBSOLV.
The generic ingredient in ZUBSOLV is buprenorphine hydrochloride; naloxone hydrochloride. There are twenty-nine drug master file entries for this API. Twenty-nine suppliers are listed for this generic product. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.
When can SIRTURO (bedaquiline fumarate) generic drug versions launch in the European Patent Office?
Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: European Patent Office Patent 2,086,940
SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.
This drug has ninety-seven patent family members in thirty-nine countries.
See drug price trends for SIRTURO.
The generic ingredient in SIRTURO is bedaquiline fumarate. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the bedaquiline fumarate profile page.
When can ZYKADIA (ceritinib) generic drug versions launch in the European Patent Office?
Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: European Patent Office Patent 2,091,918
ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.
This drug has three hundred and twenty-two patent family members in fifty-six countries.
See drug price trends for ZYKADIA.
The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.
When can ZYKADIA (ceritinib) generic drug versions launch in the European Patent Office?
Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: European Patent Office Patent 2,190,826
ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.
This drug has three hundred and twenty-two patent family members in fifty-six countries.
See drug price trends for ZYKADIA.
The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.
When can ZYKADIA (ceritinib) generic drug versions launch in the European Patent Office?
Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: European Patent Office Patent 2,311,807
ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.
This drug has three hundred and twenty-two patent family members in fifty-six countries.
See drug price trends for ZYKADIA.
The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.
When can ZYKADIA (ceritinib) generic drug versions launch in the European Patent Office?
Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: European Patent Office Patent 2,537,830
ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.
This drug has three hundred and twenty-two patent family members in fifty-six countries.
See drug price trends for ZYKADIA.
The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.
When can ZYKADIA (ceritinib) generic drug versions launch in the European Patent Office?
Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: European Patent Office Patent 3,012,249
ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.
This drug has three hundred and twenty-two patent family members in fifty-six countries.
See drug price trends for ZYKADIA.
The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.
When can LETAIRIS (ambrisentan) generic drug versions launch in the European Patent Office?
Generic name: ambrisentan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: European Patent Office Patent 2,101,777
Patent Title: COMPOSITION DE TRAITEMENT DE L'HYPERTENSION PULMONAIRE (COMPOSITION FOR TREATING A PULMONARY HYPERTENSION)
LETAIRIS is a drug marketed by Gilead. There are three patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-one patent family members in twenty-six countries. There has been litigation on patents covering LETAIRIS
See drug price trends for LETAIRIS.
The generic ingredient in LETAIRIS is ambrisentan. There are nine drug master file entries for this API. Thirteen suppliers are listed for this generic product. Additional details are available on the ambrisentan profile page.
When can XERMELO (telotristat etiprate) generic drug versions launch in the European Patent Office?
Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: European Patent Office Patent 2,091,940
XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.
This drug has seventy patent family members in twenty-nine countries.
See drug price trends for XERMELO.
The generic ingredient in XERMELO is telotristat etiprate. One supplier is listed for this generic product. Additional details are available on the telotristat etiprate profile page.
When can XERMELO (telotristat etiprate) generic drug versions launch in the European Patent Office?
Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: European Patent Office Patent 2,589,600
XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.
This drug has seventy patent family members in twenty-nine countries.
See drug price trends for XERMELO.
The generic ingredient in XERMELO is telotristat etiprate. One supplier is listed for this generic product. Additional details are available on the telotristat etiprate profile page.
When can XERMELO (telotristat etiprate) generic drug versions launch in the European Patent Office?
Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: European Patent Office Patent 3,808,740
XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.
This drug has seventy patent family members in twenty-nine countries.
See drug price trends for XERMELO.
The generic ingredient in XERMELO is telotristat etiprate. One supplier is listed for this generic product. Additional details are available on the telotristat etiprate profile page.
When can PICATO (ingenol mebutate) generic drug versions launch in the European Patent Office?
Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: European Patent Office Patent 2,399,571
Patent Title: Compositions thérapeutiques comprenant de l'ingénol-2-angelate (Therapeutic compositions comprising ingenol-3-angelate)
This drug has thirty-five patent family members in twenty-one countries. There has been litigation on patents covering PICATO
See drug price trends for PICATO.
The generic ingredient in PICATO is ingenol mebutate. There are three drug master file entries for this API. Additional details are available on the ingenol mebutate profile page.
When can VYKAT XR (diazoxide choline) generic drug versions launch in the European Patent Office?
Generic name: diazoxide choline
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2026
Generic Entry Controlled by: European Patent Office Patent 1,968,601
Patent Title: SELS D'OUVREURS DES CANAUX POTASSIQUES ATP-DÉPENDANTS ET LEURS UTILISATIONS (SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF)
VYKAT XR is a drug marketed by Soleno Therap. There are six patents protecting this drug.
This drug has seventy-nine patent family members in twenty-two countries.
The generic ingredient in VYKAT XR is diazoxide choline. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the diazoxide choline profile page.
When can VYKAT XR (diazoxide choline) generic drug versions launch in the European Patent Office?
Generic name: diazoxide choline
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2026
Generic Entry Controlled by: European Patent Office Patent 2,404,604
Patent Title: Sels d'ouverture de canal ATP du potassium et leurs utilisations (Salts of potassium ATP channel openers and uses thereof)
VYKAT XR is a drug marketed by Soleno Therap. There are six patents protecting this drug.
This drug has seventy-nine patent family members in twenty-two countries.
The generic ingredient in VYKAT XR is diazoxide choline. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the diazoxide choline profile page.
When can SEYSARA (sarecycline hydrochloride) generic drug versions launch in the European Patent Office?
Generic name: sarecycline hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2026
Generic Entry Controlled by: European Patent Office Patent 2,120,963
Patent Title: UTILISATION DE COMPOSÉS À BASE DE TÉTRACYCLINE SUBSTITUÉE DANS LE TRAITEMENT D'AFFECTIONS CUTANÉES INFLAMMATOIRES (SUBSTITUTED TETRACYCLINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY SKIN DISORDERS)
SEYSARA is a drug marketed by Almirall. There are four patents protecting this drug.
This drug has seventy-three patent family members in twenty countries.
See drug price trends for SEYSARA.
The generic ingredient in SEYSARA is sarecycline hydrochloride. One supplier is listed for this generic product. Additional details are available on the sarecycline hydrochloride profile page.
When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in the European Patent Office?
Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: European Patent Office Patent 2,495,016
ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has one hundred and nine patent family members in twenty-four countries. There has been litigation on patents covering ICLUSIG
See drug price trends for ICLUSIG.
The generic ingredient in ICLUSIG is ponatinib hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ponatinib hydrochloride profile page.
When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in the European Patent Office?
Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: European Patent Office Patent 3,747,441
ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has one hundred and nine patent family members in twenty-four countries. There has been litigation on patents covering ICLUSIG
See drug price trends for ICLUSIG.
The generic ingredient in ICLUSIG is ponatinib hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ponatinib hydrochloride profile page.
When can EPSOLAY (benzoyl peroxide) generic drug versions launch in the European Patent Office?
Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: European Patent Office Patent 2,118,208
Patent Title: MÉTHODE DE PRÉPARATION DE PARTICULES COMPRENANT UN ENROBAGE D'OXYDE MÉTALLIQUE (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING)
This drug has fifty-one patent family members in fifteen countries. There has been litigation on patents covering EPSOLAY
See drug price trends for EPSOLAY.
The generic ingredient in EPSOLAY is benzoyl peroxide. There are seventeen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the benzoyl peroxide profile page.
When can EPSOLAY (benzoyl peroxide) generic drug versions launch in the European Patent Office?
Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: European Patent Office Patent 2,545,776
Patent Title: Procédé de préparation de particules comprenant un revêtement d'oxyde métallique et particules à revêtement d'oxyde métallique (Method for preparing particles comprising metal oxide coating and particles with metal oxide coating)
This drug has fifty-one patent family members in fifteen countries. There has been litigation on patents covering EPSOLAY
See drug price trends for EPSOLAY.
The generic ingredient in EPSOLAY is benzoyl peroxide. There are seventeen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the benzoyl peroxide profile page.
When can NESINA (alogliptin benzoate) generic drug versions launch in the European Patent Office?
Generic name: alogliptin benzoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: European Patent Office Patent 2,124,901
Patent Title: PRÉPARATION DE COMPRIMÉ NE PROVOQUANT PAS DE PROBLÈME DE PASTILLAGE (TABLET PREPARATION WITHOUT CAUSING A TABLETING TROUBLE)
This drug has sixty-nine patent family members in thirty-seven countries. There has been litigation on patents covering NESINA
See drug price trends for NESINA.
The generic ingredient in NESINA is alogliptin benzoate. There are ten drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate profile page.
When can MACRILEN (macimorelin acetate) generic drug versions launch in the European Patent Office?
Generic name: macimorelin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 19, 2027
Generic Entry Controlled by: European Patent Office Patent 1,984,744
MACRILEN is a drug marketed by Aeterna Zentaris. There is one patent protecting this drug.
This drug has eleven patent family members in ten countries.
See drug price trends for MACRILEN.
The generic ingredient in MACRILEN is macimorelin acetate. Two suppliers are listed for this generic product. Additional details are available on the macimorelin acetate profile page.
When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in the European Patent Office?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: European Patent Office Patent 2,079,445
PANCREAZE is a drug marketed by
This drug has eleven patent family members in ten countries.
See drug price trends for PANCREAZE.
The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in the European Patent Office?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: European Patent Office Patent 2,079,445
ZENPEP is a drug marketed by
This drug has eleven patent family members in ten countries.
See drug price trends for ZENPEP.
The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can PRESTALIA (amlodipine besylate; perindopril arginine) generic drug versions launch in the European Patent Office?
Generic name: amlodipine besylate; perindopril arginine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 26, 2027
Generic Entry Controlled by: European Patent Office Patent 1,989,182
PRESTALIA is a drug marketed by Adhera. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has thirty patent family members in twenty-seven countries. There has been litigation on patents covering PRESTALIA
The generic ingredient in PRESTALIA is amlodipine besylate; perindopril arginine. There are fifty drug master file entries for this API. Additional details are available on the amlodipine besylate; perindopril arginine profile page.
When can DYANAVEL XR (amphetamine) generic drug versions launch in the European Patent Office?
Generic name: amphetamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2027
Generic Entry Controlled by: European Patent Office Patent 2,428,205
Patent Title: Formulations à libération modifiée contenant des complexes médicament - résine échangeuse d'ions (Modified release formulations containing drug-ion exchange resin complexes)
This drug has twenty-one patent family members in fourteen countries. There has been litigation on patents covering DYANAVEL XR
See drug price trends for DYANAVEL XR.
The generic ingredient in DYANAVEL XR is amphetamine. There are fifty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the amphetamine profile page.
When can TUZISTRA XR (chlorpheniramine polistirex; codeine polistirex) generic drug versions launch in the European Patent Office?
Generic name: chlorpheniramine polistirex; codeine polistirex
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2027
Generic Entry Controlled by: European Patent Office Patent 2,428,205
Patent Title: Formulations à libération modifiée contenant des complexes médicament - résine échangeuse d'ions (Modified release formulations containing drug-ion exchange resin complexes)
TUZISTRA XR is a drug marketed by Tris Pharma Inc. There are two patents protecting this drug.
This drug has twenty-one patent family members in fourteen countries. There has been litigation on patents covering TUZISTRA XR
See drug price trends for TUZISTRA XR.
The generic ingredient in TUZISTRA XR is chlorpheniramine polistirex; codeine polistirex. There are twenty-nine drug master file entries for this API. Additional details are available on the chlorpheniramine polistirex; codeine polistirex profile page.
When can SPRAVATO (esketamine hydrochloride) generic drug versions launch in the European Patent Office?
Generic name: esketamine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: European Patent Office Patent 2,012,762
Patent Title: ADMINISTRATION INTRA-NASALE DE KETAMINE POUR TRAITER LA DEPRESSION (INTRANASAL ADMINISTRATION OF KETAMINE TO TREAT DEPRESSION)
This drug has sixty-two patent family members in twenty-four countries. There has been litigation on patents covering SPRAVATO
See drug price trends for SPRAVATO.
The generic ingredient in SPRAVATO is esketamine hydrochloride. One supplier is listed for this generic product. Additional details are available on the esketamine hydrochloride profile page.
When can XENLETA (lefamulin acetate) generic drug versions launch in the European Patent Office?
Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: European Patent Office Patent 1,972,618
XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug.
This drug has one hundred and twenty patent family members in thirty-six countries. There has been litigation on patents covering XENLETA
See drug price trends for XENLETA.
The generic ingredient in XENLETA is lefamulin acetate. One supplier is listed for this generic product. Additional details are available on the lefamulin acetate profile page.
When can XENLETA (lefamulin acetate) generic drug versions launch in the European Patent Office?
Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: European Patent Office Patent 2,137,143
XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug.
This drug has one hundred and twenty patent family members in thirty-six countries. There has been litigation on patents covering XENLETA
See drug price trends for XENLETA.
The generic ingredient in XENLETA is lefamulin acetate. One supplier is listed for this generic product. Additional details are available on the lefamulin acetate profile page.
When can VARUBI (rolapitant hydrochloride) generic drug versions launch in the European Patent Office?
Generic name: rolapitant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 22, 2027
Generic Entry Controlled by: European Patent Office Patent 2,136,793
Patent Title: FORMULATIONS POUR COMPRIMÉS CONTENANT DES SELS DE 8-[{1-(3,5-BIS- (TRIFLUOROMÉTHYL)PHÉNYL)-ÉTHOXY}-MÉTHYL]-8-PHÉNYL-1,7-DIAZA-SPIRO[4,5]- DÉCAN-2-ONE ET COMPRIMÉS (TABLET FORMULATIONS CONTAINING 8-[{1-(3,5-BIS-(TRIFLUOROMETHYL)PHENYL)-ETHOXY}-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE SALTS AND TABLETS MADE THEREFROM)
VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.
This drug has one hundred and fifty-eight patent family members in thirty-five countries.
The generic ingredient in VARUBI is rolapitant hydrochloride. One supplier is listed for this generic product. Additional details are available on the rolapitant hydrochloride profile page.
When can AMYVID (florbetapir f-18) generic drug versions launch in the European Patent Office?
Generic name: florbetapir f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 26, 2027
Generic Entry Controlled by: European Patent Office Patent 2,363,391
AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug.
This drug has fifty-one patent family members in thirty-three countries. There has been litigation on patents covering AMYVID
The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this generic product. Additional details are available on the florbetapir f-18 profile page.
When can AMYVID (florbetapir f-18) generic drug versions launch in the European Patent Office?
Generic name: florbetapir f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 26, 2027
Generic Entry Controlled by: European Patent Office Patent 2,363,392
AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug.
This drug has fifty-one patent family members in thirty-three countries. There has been litigation on patents covering AMYVID
The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this generic product. Additional details are available on the florbetapir f-18 profile page.
When can EDARBI (azilsartan kamedoxomil) generic drug versions launch in the European Patent Office?
Generic name: azilsartan kamedoxomil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 28, 2027
Generic Entry Controlled by: European Patent Office Patent 2,124,903
Patent Title: COMPOSITION PHARMACEUTIQUE SOLIDE COMPRENANT UN DÉRIVÉ DE BENZIMIDAZOLE-7-CARBOXYLATE ET UN AGENT DE CONTRÔLE DU PH (SOLID PHARMACEUTICAL COMPOSITION COMPRISING A BENZIMIDAZOLE-7-CARBOXYLATE DERIVATIVE AND A PH CONTROL AGENT)
This drug has twenty-one patent family members in seventeen countries. There has been litigation on patents covering EDARBI
See drug price trends for EDARBI.
The generic ingredient in EDARBI is azilsartan kamedoxomil. There are six drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the azilsartan kamedoxomil profile page.
When can VARUBI (rolapitant hydrochloride) generic drug versions launch in the European Patent Office?
Generic name: rolapitant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 04, 2027
Generic Entry Controlled by: European Patent Office Patent 2,662,373
VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.
This drug has one hundred and fifty-eight patent family members in thirty-five countries.
The generic ingredient in VARUBI is rolapitant hydrochloride. One supplier is listed for this generic product. Additional details are available on the rolapitant hydrochloride profile page.
When can VARUBI (rolapitant hydrochloride) generic drug versions launch in the European Patent Office?
Generic name: rolapitant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 04, 2027
Generic Entry Controlled by: European Patent Office Patent 2,662,374
VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.
This drug has one hundred and fifty-eight patent family members in thirty-five countries.
The generic ingredient in VARUBI is rolapitant hydrochloride. One supplier is listed for this generic product. Additional details are available on the rolapitant hydrochloride profile page.
When can INLYTA (axitinib) generic drug versions launch in the European Patent Office?
Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: European Patent Office Patent 2,134,702
Patent Title: FORMES CRISTALLINES DE 6-[2-(METHYLCARBAMOYL)PHENYLSULFANYL]-3-E-[2-(PYRIDIN-2-YL)ETHENYL]INDAZOLE UTILES POUR LE TRAITEMENT D'UNE CROISSANCE CELLULAIRE ANORMALE CHEZ DES MAMMIFERES (CRYSTALLINE FORMS OF 6-[2-(METHYLCARBAMOYL)PHENYLSULFANYL]-3-E-[2-(PYRIDIN-2-YL)ETHENYL]INDAZOLE SUITABLE FOR THE TREATMENT OF ABNORMAL CELL GROWTH IN MAMMALS)
INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has one hundred and two patent family members in thirty-one countries. There has been litigation on patents covering INLYTA
See drug price trends for INLYTA.
The generic ingredient in INLYTA is axitinib. There are four drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the axitinib profile page.
When can INLYTA (axitinib) generic drug versions launch in the European Patent Office?
Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: European Patent Office Patent 3,252,047
Patent Title: FORMES CRISTALLINES DE 6-[2-(METHYLCARBAMOYL)PHENYLSULFANYL]-3-E-[2-(PYRIDIN-2-YL)ETHENYL]INDAZOLE UTILES POUR LE TRAITEMENT D'UNE CROISSANCE CELLULAIRE ANORMALE CHEZ DES MAMMIFERES (CRYSTALLINE FORMS OF 6-[2-(METHYLCARBAMOYL)PHENYLSULFANYL]-3-E-[2-(PYRIDIN-2-YL)ETHENYL]INDAZOLE SUITABLE FOR THE TREATMENT OF ABNORMAL CELL GROWTH IN MAMMALS)
INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has one hundred and two patent family members in thirty-one countries. There has been litigation on patents covering INLYTA
See drug price trends for INLYTA.
The generic ingredient in INLYTA is axitinib. There are four drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the axitinib profile page.
When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in the European Patent Office?
Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: European Patent Office Patent 2,007,756
Patent Title: MODULATEURS DES TRANSPORTEURS DE CASSETTES DE LIAISON DE L'ATP (MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS)
SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug.
This drug has four hundred and twenty-eight patent family members in forty-one countries. There has been litigation on patents covering SYMDEKO (COPACKAGED)
The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.
When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in the European Patent Office?
Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: European Patent Office Patent 2,674,428
Patent Title: Modulateurs des transporteurs de cassettes de liaison de l'ATP (Modulators of ATP-binding cassette transporters)
SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug.
This drug has four hundred and twenty-eight patent family members in forty-one countries. There has been litigation on patents covering SYMDEKO (COPACKAGED)
The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.
When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in the European Patent Office?
Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: European Patent Office Patent 3,091,011
Patent Title: MODULATEURS DE TRANSPORTEURS DE CASSETTE À LIAISON ATP (MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS)
SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug.
This drug has four hundred and twenty-eight patent family members in forty-one countries. There has been litigation on patents covering SYMDEKO (COPACKAGED)
The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.
When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in the European Patent Office?
Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: European Patent Office Patent 3,327,016
Patent Title: PRÉPARATION DES MODULATEURS DE TRANSPORTEURS DE CASSETTE À LIAISON ATP (PREPARATION OF MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS)
SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug.
This drug has four hundred and twenty-eight patent family members in forty-one countries. There has been litigation on patents covering SYMDEKO (COPACKAGED)
The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.
When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in the European Patent Office?
Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: European Patent Office Patent 3,882,245
Patent Title: MODULATEURS DE TRANSPORTEURS DE CASSETTE À LIAISON ATP (MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS)
SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug.
This drug has four hundred and twenty-eight patent family members in forty-one countries. There has been litigation on patents covering SYMDEKO (COPACKAGED)
The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.
When can QVAR REDIHALER (beclomethasone dipropionate) generic drug versions launch in the European Patent Office?
Generic name: beclomethasone dipropionate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 11, 2027
Generic Entry Controlled by: European Patent Office Patent 2,135,199
This drug has two hundred and seventy-eight patent family members in twenty-seven countries. There has been litigation on patents covering QVAR REDIHALER
See drug price trends for QVAR REDIHALER.
The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the beclomethasone dipropionate profile page.
When can PROMACTA (eltrombopag olamine) generic drug versions launch in the European Patent Office?
Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: European Patent Office Patent 2,152,237
Patent Title: NOUVELLE COMPOSITION PHARMACEUTIQUE (NOVEL PHARMACEUTICAL COMPOSITION)
PROMACTA is a drug marketed by Novartis. There are six patents protecting this drug and two Paragraph IV challenges.
This drug has one hundred and thirty-five patent family members in forty-one countries. There has been litigation on patents covering PROMACTA
See drug price trends for PROMACTA.
The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the eltrombopag olamine profile page.
When can PROMACTA (eltrombopag olamine) generic drug versions launch in the European Patent Office?
Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: European Patent Office Patent 4,218,732
Patent Title: COMPRIMÉS COMPRENANTS DE L'ELTROMBOPAG OLAMINE (TABLETS COMPRISING ELTROMBOPAG OLAMINE)
PROMACTA is a drug marketed by Novartis. There are six patents protecting this drug and two Paragraph IV challenges.
This drug has one hundred and thirty-five patent family members in forty-one countries. There has been litigation on patents covering PROMACTA
See drug price trends for PROMACTA.
The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the eltrombopag olamine profile page.
When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in the European Patent Office?
Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: European Patent Office Patent 2,023,933
ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has one hundred and nine patent family members in twenty-four countries. There has been litigation on patents covering ICLUSIG
See drug price trends for ICLUSIG.
The generic ingredient in ICLUSIG is ponatinib hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ponatinib hydrochloride profile page.
When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in the European Patent Office?
Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: European Patent Office Patent 2,024,366
ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has one hundred and nine patent family members in twenty-four countries. There has been litigation on patents covering ICLUSIG
See drug price trends for ICLUSIG.
The generic ingredient in ICLUSIG is ponatinib hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ponatinib hydrochloride profile page.
When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in the European Patent Office?
Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: European Patent Office Patent 2,155,696
This drug has one hundred and twenty-one patent family members in forty-two countries. There has been litigation on patents covering VRAYLAR
See drug price trends for VRAYLAR.
The generic ingredient in VRAYLAR is cariprazine hydrochloride. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cariprazine hydrochloride profile page.
When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in the European Patent Office?
Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: European Patent Office Patent 2,164,473
SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.
This drug has one hundred and twenty-one patent family members in forty-two countries.
See drug price trends for SIGNIFOR LAR.
The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. One supplier is listed for this generic product. Additional details are available on the pasireotide pamoate profile page.
When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in the European Patent Office?
Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: European Patent Office Patent 3,666,263
SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.
This drug has one hundred and twenty-one patent family members in forty-two countries.
See drug price trends for SIGNIFOR LAR.
The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. One supplier is listed for this generic product. Additional details are available on the pasireotide pamoate profile page.
When can CONTRAVE (bupropion hydrochloride; naltrexone hydrochloride) generic drug versions launch in the European Patent Office?
Generic name: bupropion hydrochloride; naltrexone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 31, 2027
Generic Entry Controlled by: European Patent Office Patent 3,626,236
Patent Title: FORMULATION DE NALTREXONE À LIBÉRATION PROLONGÉE (SUSTAINED RELEASE FORMULATION OF NALTREXONE)
CONTRAVE is a drug marketed by Nalpropion. There are eighteen patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and twenty-eight patent family members in forty-five countries. There has been litigation on patents covering CONTRAVE
See drug price trends for CONTRAVE.
The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.
When can TRELSTAR (triptorelin pamoate) generic drug versions launch in the European Patent Office?
Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: European Patent Office Patent 2,164,467
TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.
This drug has forty-seven patent family members in thirty-two countries.
See drug price trends for TRELSTAR.
The generic ingredient in TRELSTAR is triptorelin pamoate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the triptorelin pamoate profile page.
When can TRELSTAR (triptorelin pamoate) generic drug versions launch in the European Patent Office?
Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: European Patent Office Patent 2,500,014
TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.
This drug has forty-seven patent family members in thirty-two countries.
See drug price trends for TRELSTAR.
The generic ingredient in TRELSTAR is triptorelin pamoate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the triptorelin pamoate profile page.
When can TRELSTAR (triptorelin pamoate) generic drug versions launch in the European Patent Office?
Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: European Patent Office Patent 3,431,077
TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.
This drug has forty-seven patent family members in thirty-two countries.
See drug price trends for TRELSTAR.
The generic ingredient in TRELSTAR is triptorelin pamoate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the triptorelin pamoate profile page.
When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in the European Patent Office?
Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: European Patent Office Patent 2,164,467
TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.
This drug has forty-seven patent family members in thirty-two countries.
The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the triptorelin pamoate profile page.
When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in the European Patent Office?
Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: European Patent Office Patent 2,500,014
TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.
This drug has forty-seven patent family members in thirty-two countries.
The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the triptorelin pamoate profile page.
When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in the European Patent Office?
Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: European Patent Office Patent 3,431,077
TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.
This drug has forty-seven patent family members in thirty-two countries.
The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the triptorelin pamoate profile page.
When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in the European Patent Office?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: European Patent Office Patent 2,173,752
Patent Title: SELS DE L'INHIBITEUR (R)-3-(4-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE DE LA JANUS KINASE (SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE)
JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JAKAFI
See drug price trends for JAKAFI.
The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.
When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in the European Patent Office?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: European Patent Office Patent 2,740,731
Patent Title: Sels cristallines de l'inhibiteur de janus kinase (r)-3-(4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl)-1h-pyrazol-1-yl) -3-cyclopentylpropanenitrile (CRYSTALLINE SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE)
JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JAKAFI
See drug price trends for JAKAFI.
The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.
When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in the European Patent Office?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: European Patent Office Patent 3,070,090
Patent Title: UTILISATION DES SELS DE L'INHIBITEUR DE JANUS KINASE (R)-3-(4- (7H-PYRROLO [2,3-D] PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL) -3-CYCLOPENTYLPROPANENITRILE (USE OF SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H- PYRAZOL-1-YL)-3- CYCLOPENTYLPROPANENITRILE)
JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JAKAFI
See drug price trends for JAKAFI.
The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.
When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in the European Patent Office?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: European Patent Office Patent 3,495,369
Patent Title: UTILISATION DES SELS DE L'INHIBITEUR DE JANUS KINASE (R)-3-(4-(7H-PYRROLO [2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE (USE OF SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H- PYRAZOL-1-YL)-3- CYCLOPENTYLPROPANENITRILE)
JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JAKAFI
See drug price trends for JAKAFI.
The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.
When can KYBELLA (deoxycholic acid) generic drug versions launch in the European Patent Office?
Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: European Patent Office Patent 2,069,383
Patent Title: COMPOSITION, PROCÉDÉ ET PRÉPARATION D'ACIDE BILIAIRE SYNTHÉTIQUE (SYNTHETIC BILE ACID COMPOSITION, METHOD, AND PREPARATION)
KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and forty-six patent family members in thirty-eight countries. There has been litigation on patents covering KYBELLA
The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the deoxycholic acid profile page.
When can KYBELLA (deoxycholic acid) generic drug versions launch in the European Patent Office?
Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: European Patent Office Patent 2,407,475
Patent Title: préparation synthétique d'acide biliaire (synthetic bile acid preparation)
KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and forty-six patent family members in thirty-eight countries. There has been litigation on patents covering KYBELLA
The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the deoxycholic acid profile page.
When can KYBELLA (deoxycholic acid) generic drug versions launch in the European Patent Office?
Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: European Patent Office Patent 3,002,290
Patent Title: SYNTHESE D'ACIDE DESOXYCHOLIQUE (DCA) (SYNTHESIS OF DEOXYCHOLIC ACID (DCA))
KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and forty-six patent family members in thirty-eight countries. There has been litigation on patents covering KYBELLA
The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the deoxycholic acid profile page.